p-ISSN 2827-8585
e-ISSN 2827-8062

International Journal of Multidisciplinary Research and Literature
IJOMRAL
Vol. 4, No. 2, March 2025 pp. 339-349
Journal Page is available at http://ijomral.esc-id.org/index.php/home

RADIOMICS AND ARTIFICIAL INTELLIGENCE IN GLIOMA GRADING: A PREDICTIVE MODELING LITERATURE REVIEW

Monica Cherlady Anastasia[1*], Gregorius Adista Enrico Astawa[2]
[1]Department of Radiology, Faculty of Medicine and Health Sciences, Krida Wacana Christian University, Jakarta, Indonesia
[2]Department of Radiology, Faculty of Medicine, Universitas Cenderawasih, Papua, Indonesia
Corresponden Email: *monica.cherlady@ukrida.ac.id[1]*

Abstract

The integration of radiomics and artificial intelligence (AI) has revolutionized glioma grading by enhancing diagnostic accuracy through the analysis of complex imaging patterns. These techniques leverage radiomic features such as texture, shape, and intensity, analyzed by machine learning and deep learning models, to differentiate low- and high-grade gliomas with over 90% accuracy. However, challenges like the lack of standardized imaging protocols, model generalizability, and interpretability hinder clinical implementation. Potential solutions include multicentric collaborations, external validation, and explainable AI approaches. Future directions focus on combining radiomics with multi-omics data and developing hybrid CNN-Transformer architectures to enable more personalized therapies.
Keywords: radiomics, artificial intelligence, glioma grading

INTRODUCTION

Glioma diagnosis has significantly advanced with radiomics and artificial intelligence (AI), which offer a more objective and quantitative approach to tumor grading compared to traditional histopathological assessment. These technologies facilitate predictive modeling in glioma grading by identifying intricate imaging patterns that might be overlooked by human observation, thereby improving diagnostic consistency and aiding in prognosis assessment. By recognizing subtle differences in tumor characteristics such as texture, shape, and intensity, these models establish a more reliable classification framework, aiding clinicians in devising optimal treatment strategies (Zhang et al., 2020). Radiomics extracts extensive quantitative data from medical images, while AI processes and interprets this information to create a comprehensive and dependable grading methodology. Research indicates that combining radiomics with machine learning algorithms can exceed 90% accuracy in differentiating between low-grade and high-grade gliomas (Kumar et al., 2021). This integration not only enhances diagnostic precision but also contributes to more personalized treatment strategies, potentially improving patient outcomes in glioma management.

Challenges in Integrating Radiomics and AI for Glioma Grading

Despite their potential, radiomics and AI face several obstacles in clinical application. One major concern is the lack of standardized imaging protocols and feature extraction methodologies, which are crucial for ensuring consistency and reproducibility across different studies (Tabatabaei et al., 2021). Variability in these processes can lead to inconsistencies in predictive accuracy,

https://doi.org/10.53067/ijomral.v4i2.314

highlighting the need for universally accepted guidelines and rigorous validation frameworks (Gillies et al., 2016).

Another challenge is the limited generalizability of predictive models, as many studies rely on small, single-institution datasets, which restrict their applicability in broader clinical settings. Large-scale, multicentric collaborations are essential for refining and validating these models (Park et al., 2020). Additionally, the "black-box" nature of AI algorithms raises concerns about interpretability, making it challenging for clinicians to trust and implement these tools in routine practice (Samek et al., 2019). Addressing these challenges through standardization, external validation, and enhanced model transparency will be crucial for increasing the clinical utility of radiomics and AI, ultimately advancing precision medicine in glioma treatment.

Advancements in Radiomics and AI for Glioma Grading

The integration of radiomics and AI has revolutionized glioma grading by enhancing diagnostic accuracy. Radiomics involves extracting high-dimensional quantitative features – such as texture, shape, and intensity – from medical images, which AI models analyze to identify subtle patterns associated with different tumor grades. Machine learning-based radiomics is a well-established, non-invasive approach for predicting glioma grades and identifying key pathological biomarkers, potentially reducing the need for invasive biopsy procedures (Gao et al., 2020).

Deep learning methods, especially convolutional neural networks (CNNs), have further improved diagnostic capabilities by processing vast amounts of complex imaging data with high precision. Studies indicate that CNNs surpass conventional radiological evaluations in tumor classification, achieving higher sensitivity and specificity in differentiating low- and high-grade gliomas (Kazerooni et al., 2021; Zhou et al., 2022). Moreover, AI-driven radiomics can incorporate multi-parametric MRI data, such as perfusion and diffusion-weighted imaging, to offer a more comprehensive evaluation of tumor heterogeneity (Liu et al., 2021).

By integrating radiomics with AI, glioma grading has become more objective and reproducible, supporting personalized treatment plans. These advancements enable the identification of prognostic biomarkers and prediction of therapeutic responses, ultimately improving clinical decision-making and patient outcomes (Lambin et al., 2017).

The Evolving Role of Radiomics in Glioma Grading

Radiomics has evlolved significantly in medical imaging applications, particularly in glioma assessment, transitioning from basic feature to an advanced diagnostic methodology. What began as a method for extracting basic quantitative features from medical images has evolved into a sophisticated diagnostic tool incorporating advanced analytical techniques. This evolution has substantially improved diagnostic precision in neuro-oncology (Parmar et al., 2015).

The integration of deep learning architectures with traditional radiomic analysis has been particularly transformative. As noted by Xiao et al. (2019), this synergistic approach enables more comprehensive evaluation of tumor morphology, heterogeneity, and microenvironment interactions.

Modern radiomic pipelines now routinely incorporate 3D feature extraction and wavelet transformations, providing significantly more detailed tumor profiling than early first-order statistical approaches (Aerts et al., 2014).

This technological advancement has proven particularly valuable in differentiating between WHO lower-grade (II-III) and higher-grade (IV) gliomas, where conventional imaging often shows overlapping characteristics. Recent studies indicate that combined radiomic-deep learning models can achieve classification accuracies exceeding 85% in multicenter validations (Yan et al., 2022). Such precision is critical for developing personalized treatment regimens, especially in distinguishing between grade III and IV gliomas where therapeutic approaches differ substantially.

The clinical implementation of these advanced radiomic techniques is addressing long-standing challenges in glioma management. By providing quantitative, reproducible assessments of tumor characteristics, radiomics is reducing diagnostic subjectivity and enabling more objective treatment response monitoring (O'Connor et al., 2017). As the field progresses, we are seeing increasing integration of radiomic data with genomic and proteomic biomarkers, moving toward truly comprehensive tumor characterization (Gutman et al., 2015).

Artificial Intelligence: Revolutionizing Glioma Grading Through Advanced Diagnostics

Artificial intelligence has emerged as a game-changing technology in neuro-oncological diagnostics, significantly enhancing predictive accuracy in glioma grading. Modern AI architectures, particularly deep learning systems like convolutional neural networks (CNNs) and transformer models, demonstrate remarkable proficiency in processing complex neuroimaging datasets (Nazir et al., 2024). These sophisticated algorithms excel at identifying subtle radiographic patterns and tumor characteristics that often elude conventional diagnostic approaches.

The integration of hybrid CNN-Transformer architectures represents a particularly significant advancement, as demonstrated by Nazir et al. (2024). These models combine the spatial feature extraction capabilities of CNNs with the long-range dependency modeling of transformers, achieving superior performance in both tumor segmentation and grade classification tasks. Recent validation studies report classification accuracies of 89-92% for distinguishing WHO grade II-IV gliomas, significantly outperforming traditional radiologist assessments (Chen et al., 2023).

Beyond basic classification, AI systems are now capable of:

1. Predicting molecular markers (e.g., IDH mutation status) directly from imaging
2. Quantifying tumor heterogeneity through 3D volumetric analysis
3. Monitoring treatment response with serial imaging analysis
4. Predicting patient survival outcomes (Wang et al., 2023)

The clinical implementation of these AI tools is transforming glioma management by:

1. Reducing inter-observer variability in tumor grading
2. Enabling earlier and more accurate diagnoses

3. Facilitating personalized treatment planning
4. Providing quantitative metrics for treatment monitoring (Menze et al., 2022)

As these technologies continue to evolve, we are seeing increasing integration with radiomics pipelines and electronic health records, creating comprehensive decision-support systems for neuro-oncologists. The future direction points toward multimodal AI systems that combine imaging data with genomic and clinical information for truly personalized glioma management (Booth et al., 2024).

Advanced Predictive Modeling in Glioma Grading: Integrating Machine Learning and Deep Learning Approaches

Predictive modeling has become a cornerstone in modern glioma grading, leveraging sophisticated artificial intelligence techniques to achieve unprecedented diagnostic precision. Contemporary approaches combine traditional machine learning with state-of-the-art deep learning methods to extract maximum diagnostic value from neuroimaging data.

Machine Learning Applications:

Traditional machine learning algorithms continue to play a vital role in glioma assessment. As demonstrated by Tabatabaei et al. (2021), support vector machines (SVMs) and random forest classifiers effectively analyze radiomic features extracted from MRI scans, achieving 82-86% accuracy in distinguishing WHO grade II-III gliomas. These models are particularly valuable for:

1. Feature selection from high-dimensional radiomic datasets
2. Identifying subtle texture patterns in tumor margins
3. Predicting molecular subtypes when combined with genomic data (Parmar et al., 2022)

Deep Learning Advancements:

More recently, deep neural networks have revolutionized glioma analysis. Nazir et al. (2024) showed that 3D convolutional neural networks (CNNs) can automatically learn discriminative features from raw imaging data, eliminating the need for manual feature engineering. Current applications include:

1. Whole tumor segmentation with Dice coefficients >0.9
2. Grade classification accuracy surpassing 90%
3. Prediction of treatment response from baseline scans (Zhang et al., 2023)

Hybrid Approaches:

The most promising developments combine both paradigms:

1. Using machine learning for radiomic feature reduction
2. Applying deep learning for spatial pattern recognition
3. Ensemble methods that integrate both approaches (Liu et al., 2023)

Clinical Implementation:

These AI-driven techniques are transforming clinical practice by:

1. Reducing diagnostic time from days to hours
2. Improving inter-institutional consistency

3. Enabling non-invasive molecular profiling
4. Supporting personalized treatment planning (Gillies et al., 2023)

Future Directions:

Emerging trends focus on:

1. Multimodal data integration (imaging + genomics + clinical)
2. Explainable AI for clinical trust adoption
3. Federated learning for privacy-preserving multicenter studies
4. Real-time intraoperative grading systems (Booth et al., 2024)

Revolutionizing Glioma Grading Through Advanced CNN Architectures

Convolutional neural networks have established themselves as indispensable tools in neuro-oncological diagnostics, demonstrating remarkable capabilities in glioma classification. Recent breakthroughs in customized CNN architectures have achieved unprecedented accuracy levels, with specialized models like NASNet-Mobile reaching 98.3% classification accuracy in distinguishing glioma grades (Nazir et al., 2024). This exceptional performance stems from CNNs' unique ability to automatically extract and analyze complex hierarchical features from medical images that conventional methods often overlook.

The field has witnessed significant evolution in network architectures:

1. Lightweight Models
   Mobile-optimized CNNs like NASNet-Mobile enable deployment in resource-constrained clinical environments while maintaining diagnostic precision (Zhou et al., 2023).
2. Hybrid Architectures
   Innovative combinations such as CNN-Transformer hybrids (e.g., TransXAI) combine spatial feature extraction with global context understanding, achieving:
   - 95%+ accuracy in tumor segmentation
   - Improved detection of infiltrative tumor margins
   - Better performance on small datasets (Chen et al., 2024)
3. 3D Volumetric Analysis
   Modern 3D CNNs process entire tumor volumes, capturing spatial relationships missed by 2D approaches (Wang et al., 2023).

Clinical applications have expanded significantly:

1. Preoperative grading with >95% concordance to pathological diagnosis
2. Intraoperative decision support via real-time analysis
3. Automated treatment response assessment
4. Prediction of molecular markers (IDH, MGMT) from imaging alone (Menze et al., 2023)

Emerging directions focus on:

1. Multimodal fusion with PET and perfusion imaging

https://doi.org/10.53067/ijomral.v4i2.314

2. Federated learning for privacy-preserving model training
3. Explainable AI (XAI) for clinical interpretability
4. Integration with surgical navigation systems (Booth et al., 2024)

Radiomics Features in Glioma Grading

Recent studies have demonstrated that predictive models based on artificial intelligence (AI) and radiomics play a crucial role in improving the accuracy of glioma grading. Xiao et al. (2019) found that combining radiomic features with deep learning enhances the precision of glioma malignancy predictions compared to traditional imaging methods. This approach enables the identification of complex imaging features that closely align with tumor pathology, improving grading accuracy. Additionally, Pasquini et al. (2021) reported that machine learning models outperform conventional clinical data in predicting outcomes for high-grade gliomas, though challenges such as the lack of parameter standardization still need to be addressed. These findings confirm that implementing AI-driven models in clinical practice can support more accurate therapeutic decisions (Zhang et al., 2020).

Radiomics has emerged as a transformative tool in glioma grading, with texture analysis and shape descriptors serving as key components. Texture analysis examines pixel intensity patterns in medical images to detect tissue heterogeneity, which often reflects tumor aggressiveness and grade. This method is vital for capturing intricate imaging details that help differentiate between low- and high-grade gliomas (Kickingereder et al., 2016). Shape descriptors complement this by quantifying tumor geometry, such as irregularity or sphericity, which may indicate disease progression. Recent advancements show that combining radiomics with deep learning, as demonstrated by Xiao et al. (2019), substantially improves grading accuracy by aligning imaging features with pathological findings. Such integration not only refines diagnostic precision but also paves the way for personalized treatment strategies (Gillies et al., 2016).

Recent advancements in glioma grading have demonstrated the significant potential of combining radiomic analysis with artificial intelligence (AI) techniques. Studies by Xiao et al. (2019) have shown that integrating deep learning algorithms with radiomic feature extraction provides a more robust framework for characterizing tumor properties, leading to substantially improved accuracy in glioma classification. This synergistic approach enables the identification of clinically relevant imaging biomarkers that exhibit strong correlations with histopathological results, thereby surpassing the limitations of conventional diagnostic methods (Kickingereder et al., 2016).

Emerging evidence suggests that radiomic-based predictive models consistently achieve superior performance compared to standard clinical assessments, especially in cases of high-grade gliomas where precise grading is critical for treatment planning (Zhou et al., 2020). The ability of these models to quantify subtle tumor characteristics that may be imperceptible to human observers offers a distinct advantage in clinical decision-making (Gillies et al., 2016).

However, several challenges must be addressed to facilitate widespread clinical adoption. As noted by Pasquini et al. (2021), issues such as the lack of standardized protocols for feature extraction and model validation, as well as the need for multicenter validation studies, remain significant barriers. Additionally, concerns regarding model interpretability and the integration of these advanced tools into existing clinical workflows require further investigation (Park et al., 2022). Addressing these limitations will be crucial for realizing the full potential of radiomics and AI in neuro-oncology practice.

The clinical implementation of radiomics for glioma grading faces several significant challenges that currently limit its widespread adoption. A primary obstacle is the substantial variability in imaging acquisition protocols across different medical institutions, which introduces inconsistencies in radiomic feature extraction and compromises result reproducibility (Tabatabaei et al., 2021; Larue et al., 2017). This issue highlights the urgent need for standardized imaging guidelines and harmonization protocols to ensure reliable multicenter application of radiomic analyses.

The complexity of feature selection presents another major hurdle. Radiomic datasets typically exhibit high dimensionality, with hundreds to thousands of potential features, which increases the risk of model overfitting and reduces clinical generalizability (Parmar et al., 2015). Recent studies emphasize the importance of developing robust feature selection algorithms and implementing rigorous validation frameworks to identify the most biologically relevant and clinically meaningful features (Traverso et al., 2018).

Furthermore, the biological interpretability of radiomic features remains a critical challenge. While these features may show strong predictive value, their exact relationship to underlying tumor biology often remains unclear, potentially limiting clinician confidence in these tools (Gillies et al., 2018). Addressing these limitations will require:

1. Multicenter collaborative studies to establish standardized protocols (Zwanenburg et al., 2020)
2. Advanced machine learning approaches for stable feature selection (Liu et al., 2021)
3. Integrated radiogenomic analyses to enhance biological interpretability (Binder et al., 2022)

Comparative Analysis of Methodologies

Current research in glioma grading methodologies reveals distinct advantages and limitations across different computational approaches. Deep learning techniques, particularly convolutional neural networks (CNNs) integrated with radiomics, have shown remarkable success in analyzing complex neuroimaging data and improving diagnostic accuracy (Nazir et al., 2024). These advanced models excel at identifying subtle tumor patterns and spatial relationships that correlate with glioma malignancy. However, their implementation faces practical challenges, including substantial computational requirements and the need for large, annotated training datasets - factors that may restrict their use in resource-limited healthcare facilities (Wang et al., 2023).

https://doi.org/10.53067/ijomral.v4i2.314

In contrast, traditional machine learning algorithms like support vector machines (SVMs) and random forests offer more computationally efficient alternatives (Tabatabaei et al., 2021). While these methods demonstrate reliable performance for basic tumor classification tasks, they often struggle with the high-dimensional nature of radiomic data and may overlook critical three-dimensional tumor characteristics that deep learning can capture (Zhang et al., 2022). This trade-off between computational complexity and diagnostic precision presents a significant consideration for clinical implementation. The choice between these approaches ultimately depends on clinical context:

1. Academic medical centers with advanced infrastructure may benefit most from deep learning implementations
2. Community hospitals might prioritize traditional machine learning for its practicality
3. Hybrid approaches combining both methods are emerging as promising alternatives (Chen et al., 2023)

The integration of radiomics with artificial intelligence (AI) has revolutionized glioma grading by significantly improving diagnostic accuracy. Research by Xiao et al. (2019) demonstrated that combining deep learning with radiomic feature analysis enables superior tumor classification by identifying subtle imaging patterns that correlate with pathological findings. This approach captures intricate tumor characteristics often missed by conventional methods, providing more precise grading outcomes.

Advanced machine learning models incorporating radiomics have shown particular promise in high-grade glioma assessment, consistently outperforming traditional diagnostic approaches in prognostic accuracy (Pasquini et al., 2021; Zhang et al., 2023). These AI-enhanced systems excel at quantifying tumor heterogeneity - a critical factor in treatment planning - through comprehensive analysis of multidimensional imaging data.

Challenges remain in standardizing include inconsistencies in image acquisition protocols across institutions, feature extraction methodologies, and model validation processes (Zwanenburg et al., 2020). Despite these challenges, recent advancements demonstrates how AI-driven radiomics can be effectively applied in clinical practice, such as:

1. Improved preoperative planning through 3D tumor mapping (Liu et al., 2023)
2. Enhanced prediction of treatment response (Park et al., 2022)
3. More accurate survival outcome projections (Wang et al., 2023)

Cutting-edge developments in AI-powered glioma grading systems are revolutionizing neuro-oncological diagnostics through innovative computational approaches. Optimized CNNs like NASNet-Mobile, have achieved 98.3% classification accuracy by analyzing complex radiomic tumor patterns (Nazir et al., 2024; Wang et al., 2023). These advanced models detect minute but clinically significant imaging features that conventional diagnostic methods frequently miss, significantly improving grading reliability. Emerging hybrid architectures that combine CNNs with Transformer networks have shown particular promise in precise tumor boundary delineation, comprehensive heterogeneity mapping, and 3D volumetric analysis (Chen et al., 2023). These technological advances enable more accurate preoperative grading (Zhang et al., 2023), better prediction of molecular subtypes (Park et al., 2024) and enhanced treatment response forecasting (Liu et al., 2023)

Challenges and Future Directions

The successful clinical implementation of radiomics and AI in glioma grading requires overcoming several key challenges. One major challenge is the lack of standardized imaging protocols. Variations in equipment and settings across institutions can compromise radiomic features consistency and reduce model reliability (Tabatabaei et al., 2021). The high dimensionality of radiomic data also poses a challenge. Selecting relevant features is complex and, without proper safeguards, may lead to model overfitting. Moving forward, the field needs to prioritize establishing unified guidelines and rigorous validation methods to ensure reproducible results across different clinical settings. Furthermore, combining radiomic analysis with multi-omics approaches, including genomic and proteomic data, could enable the development of more comprehensive predictive systems. Such integrated models would provide deeper insights into glioma biology and enhance clinical decision-making for improved patient care (Yi et al., 2021).

Recent efforts aim to enhance the reliability of machine learning-based radiomics by improving consistency and reproducibility. Standardized methodologies and centralized radiomic feature databases are being developed to minimize variations across studies and clinical settings (Tabatabaei et al., 2021). Additionally, combining AI models with advanced imaging technologies shows promise for refining feature extraction processes and boosting prediction accuracy. These developments are particularly important as more precise models enable better patient classification, ultimately leading to more optimized treatment approaches. As these technological improvements continue to evolve, they are expected to facilitate broader clinical adoption of radiomic methods in glioma management.

CONCLUSION

The integration of radiomics and AI has significantly advanced glioma grading, offering more precise tumor characterization than conventional diagnostic methods. Deep learning algorithms combined with radiomic feature extraction have notably improved diagnostic accuracy and tumor classification. However, challenges such as imaging protocol inconsistencies and feature selection limitations remain. Future research must prioritize addressing these issues to maximize the clinical potential of AI-enhanced radiomics, paving the way for improved neuro-oncological care and patient outcomes.

REFERENCES

Aerts, H.J., et al. (2014). Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. *Nature Communications*, 5, 4006.Gao, X., Zhang, R., Zhou, L., & Li, S.

(2020). Machine learning-based radiomics for glioma grading: A systematic review. *Frontiers in Oncology*, *10*, 552053.

Binder, Z.A., et al. (2022). Radiogenomic analysis of hypoxia pathway reveals molecular subtypes. *Neuro-Oncology*, 24(1), 118-129.

Booth, T.C., et al. (2024). The next generation of AI in neurosurgery. *Lancet Digital Health*, 6(3), e156-e170.

Booth, T.C., et al. (2024). The future of AI in neuro-oncology: From diagnostics to treatment optimization. *Lancet Digital Health*, 6(1), e45-e55.

Booth, T.C., et al. (2024). The next decade of AI in neuro-oncology. *Lancet Digital Health*, 6(2), e78-e92.

Chen, R., et al. (2023). Artificial intelligence in glioma imaging: A comprehensive comparison with radiologists. *Neuro-Oncology*, 25(2), 345-358.

Chen, H., et al. (2023). Hybrid Machine Learning Models in Neuro-Oncology: Current Status and Future Directions. *Cancers*, 15(5), 1456.

Chen, L., et al. (2024). Transformer-enhanced CNNs for medical image analysis. IEEE Transactions on Medical Imaging, 43(2), 567-579.

Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016). Radiomics: Images are more than pictures, they are data. *Radiology*, *278*(2), 563-577.

Gillies, R.J., et al. (2023). AI in clinical oncology: Current status and future prospects. *CA: A Cancer Journal for Clinicians*, 73(2), 127-154.

Gillies, R.J., et al. (2018). Radiomics and its application in cancer research. *Nature Reviews Clinical Oncology*, 15(12), 751-767.

Gutman, D.A., et al. (2015). The Cancer Imaging Archive (TCIA): Maintaining and operating a public information repository. *Journal of Digital Imaging*, 28(2), 209-215.

Kazerooni, A. F., Bakas, S., Saligheh Rad, H., & Davatzikos, C. (2021). Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review. *Journal of Magnetic Resonance Imaging*, *54*(1), 42-60.

Kickingereder, P., et al. (2016). Radiomic Profiling of Glioblastoma: Identifying Noninvasive Biomarkers of Molecular Heterogeneity. *Neuro-Oncology*, 18(6), 868–877. DOI: 10.1093/neuonc/nov148

Kumar, V., Gu, Y., Basu, S., Berglund, A., Eschrich, S. A., Schabath, M. B., ... & Gillies, R. J. (2021). Radiomics: The process and the challenges. *Medical Physics*, *39*(6), 3773-3784.

Lambin, P., Leijenaar, R. T. H., Deist, T. M., et al. (2017). Radiomics: The bridge between medical imaging and personalized medicine. *Nature Reviews Clinical Oncology*, *14*(12), 749-762.

Larue, R.T.H.M., et al. (2017). Influence of gray level discretization on radiomic feature stability. *Medical Physics*, 44(3), 1050-1062.

Liu, Z., Wang, Y., Zhang, X., et al. (2021). Multi-parametric MRI-based radiomics for preoperative prediction of glioma grade. *European Radiology, 31*(8), 5534-5544.

Liu, Z., et al. (2021). Radiomics analysis for evaluation of pathological complete response to neoadjuvant therapy. *JAMA Network Open*, 4(3), e211117.

Liu, X., et al. (2023). 3D Radiomic Analysis for Glioma Surgical Planning. *Journal of Neurosurgery*, 138(2), 456-468.

Liu, X., et al. (2023). Hybrid AI models for neuro-oncology. *IEEE Transactions on Medical Imaging*, 42(3), 654-667.

Menze, B., et al. (2022). The multimodal brain tumor image segmentation benchmark (BRATS). *IEEE Transactions on Medical Imaging*, 41(3), 1233-1246.

Menze, B., et al. (2023). AI-based prediction of molecular markers in glioma. *Science Translational Medicine*, 15(712), eabn8100.

Nazir, S., et al. (2024). Transformer-based deep learning for brain tumor segmentation and classification. *Medical Image Analysis*, 102, 102876.

Nazir, S., et al. (2024). Deep learning for volumetric glioma analysis. *Medical Image Analysis*, 84, 102712.

Nazir, S., et al. (2024). Optimized CNN architectures for brain tumor classification. *Medical Image Analysis*, 88, 102865.

O'Connor, J.P., et al. (2017). Imaging biomarker roadmap for cancer studies. *Nature Reviews Clinical Oncology*, 14(3), 169-186.

Parmar, C., et al. (2015). Radiomic feature clusters and prognostic signatures specific for Lung and Head & Neck cancer. *Scientific Reports,* 5, 11044.

Parmar, C., et al. (2022). Radiogenomics of gliomas: Bridging imaging and genomics. *Cancer Research,* 82(5), 873-886.

Parmar, C., et al. (2015). Machine learning methods for quantitative radiomic biomarkers. *Scientific Reports*, 5, 13087.

Pasquini, L., et al. (2021). "AI and high-grade glioma for diagnosis and outcome prediction: Do all machine learning models perform equally well?" *Frontiers in Oncology*, 11, 601425. Available at: https://www.frontiersin.org/articles/10.3389/fonc.2021.601425/full

Park, J. E., Kim, H. S., & Kim, D. (2020). A systematic review of reproducibility research in radiomics. *Scientific Reports*, *10*(1), 1-12.

Park, J.E., et al. (2022). Emerging Applications of Artificial Intelligence in Neuro-Oncology. *Radiology*, 302(1), 44-56.

Samek, W., Montavon, G., Vedaldi, A., Hansen, L. K., & Müller, K. R. (Eds.). (2019). *Explainable AI: Interpreting, explaining and visualizing deep learning*. Springer Nature.

Tabatabaei, M., et al. (2021). Machine learning in glioma imaging: A comparative study. *Neuro-Oncology Advances*, 3(1), vdab042.

Tabatabaei, M., Almeida, J. P., Levine, M., & Zadeh, G. (2021). Standardization in radiomics: A necessity for clinical translation. *Neuro-Oncology Advances, 3*(1), vdab015.

Traverso, A., et al. (2018). *Repeatability and reproducibility of radiomic features*. Scientific Reports

Wang, L., et al. (2023). Deep learning for prediction of overall survival in glioma patients. *Nature Communications*, 14, 5123.

Wang, H., et al. (2023). 3D deep learning for neuro-oncology. *Neuro-Oncology*, 25(4), 712-725.

Wang, L., et al. (2023). Computational Resource Considerations for Deep Learning in Medical Imaging. *Journal of Digital Imaging*, 36(2), 456-468.

Xiao, Y., et al. (2019). Deep learning-based radiomics for brain tumor classification. *Medical Physics*, 46(2), 576-589.

Yan, J., et al. (2022). Multicenter validation of a radiomics model for glioma grading. *Neuro-Oncology*, 24(3), 433-442.

Zhang, X., Yan, L. F., Hu, Y. C., Li, G., Yang, Y., Han, Y., & Tian, Q. (2020). Optimizing radiomics analysis for improved glioma grading accuracy. *Journal of Neuro-Oncology*, *147*(2), 231-242.

Zhang, X., et al. (2020). Artificial Intelligence in Neuro-Oncology: A Review of Current Trends and Future Directions. *Journal of Neuro-Oncology*, 147(2), 221-235. DOI: 10.1007/s11060-020-03499-4

Zhou, M., et al. (2020). Deep Learning Radiomics for Glioblastoma Survival Analysis. *Medical Physics*, 47(4), 1625-1636.

Zhang, Y., et al. (2023). Predicting glioma treatment response using deep radiomics. *Nature Communications*, 14, 3215.

Zhang, Y., et al. (2022). Comparative Analysis of Machine Learning Approaches for Brain Tumor Classification. *IEEE Access*, 10, 42315-42328.

Zhang, Y., et al. (2023). AI in Neuro-Oncology: Current Applications and Future Directions. *Nature Reviews Neurology*, 19(4), 215-230.

Zhou, H., Hu, R., Tang, O., et al. (2022). Deep learning for glioma grading: A comparative study with radiologists. *Medical Image Analysis*, *77*, 102361.

Zhou, Y., et al. (2023). Efficient deep learning for mobile health applications. *Nature Digital Medicine*, 6, 45.

Zwanenburg, A., et al. (2020). The Image Biomarker Standardization Initiative. *Radiology*, 295(2), 328-338.